Major breakthrough could lead to new treatments for melanoma
December 23rd, 2010 - 2:23 pm ICT by ANILondon, Dec 23 (ANI): Researchers from Mount Sinai School of Medicine have made a major breakthrough that could lead to new treatments for patients with malignant melanoma.
They have discovered that a particular protein suppresses the progression of melanoma through regulation of an oncogene, or gene responsible for cancer growth.
Researchers studied the natural progression of melanoma using mouse and human cells, as well as patient samples and determined that the presence of a specific histone variant, which is a protein that helps package DNA, was directly related to the growth of melanoma.
In all instances, researchers observed that as the melanoma became more aggressive, the presence of the histone variant macroH2A decreased.
Researchers then manipulated macroH2A levels in melanoma and found that when they removed it in the early stages of the disease, the melanoma progressed more aggressively both in growth and metastasis. Adding macroH2A to late-stage aggressive melanoma cells created the opposite effect.
“We wanted to determine whether macroH2A is a passenger in this process or if it’s crucial in the progression of melanoma,” said Emily Bernstein, PhD, Assistant Professor of Oncological Sciences and Dermatology, Mount Sinai School of Medicine, and lead author of the study.
When further investigating macroH2A function in melanoma, the researchers found that it regulates CDK8, a known oncogene for colorectal cancer.
“CDK8 is highly expressed in aggressive melanoma, suggesting it also plays a major role in the process,” Dr. Bernstein explained.
Through further functional studies, researchers found that eliminating macroH2A led to an increase in CDK8 expression, and the elimination of CDK8 in metastatic melanoma cells impaired their proliferation. These results suggest that macroH2A suppresses melanoma progression, at least in part, through the regulation of CDK8.
“Very little is known about melanoma epigenetics or the histone-mediated epigenetic changes in cancer in general, so these findings are a major step forward in our research. As we move ahead, we would like to determine how to inhibit CDK8 function, thereby inhibiting the growth of melanoma, as well as identify additional epigenetic changes in melanoma progression. What these discoveries really highlight is the need for further studies into the epigenetic code of cancer,” said Dr. Bernstein.
The study is published in the December 23 issue of Nature. (ANI)
- Arthritis drug could help treat skin cancer - Mar 24, 2011
- Zebrafish offers skin cancer clues - Apr 06, 2011
- Possible biomarker and therapeutic target for melanoma identified - Mar 18, 2011
- Scientists discover protein that arrests cancer-spreading enzyme - Jan 04, 2011
- Key enzyme in melanoma cell development found - Jun 18, 2010
- Melanoma spreads to lungs using body's immune system - Oct 08, 2010
- Synthetic compound may lead to drugs to fight pancreatic, lung cancer - Mar 10, 2011
- Molecular approach could be the key to understanding male infertility - Aug 25, 2010
- Protein involved in melanoma's development identified - Dec 24, 2010
- Scientists complete whole-exome sequencing of skin cancer - Apr 16, 2011
- Mechanism that turns healthy cells into prostate cancer cells discovered - Dec 03, 2010
- Cancer research finds two genetic variants - Oct 10, 2011
- Key step for regulating embryonic development discovered - Apr 23, 2010
- Scientists discover new way diseases develop - Jul 09, 2010
- Ultraviolet light 'helps skin cancer cells survive, proliferate' - Dec 08, 2010
Tags: aggressive melanoma, cancer growth, dr bernstein, emily bernstein, epigenetics, functional studies, growth researchers, histone, human cells, malignant melanoma, melanoma, melanoma cells, mount sinai school, mount sinai school of medicine, natural progression, oncogene, oncological sciences, patient samples, phd assistant, school of medicine